Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
EXJADE® (deferasirox)
- www.exjade.com
(For Non U.S. Health Care Professionals Only)
EXJADE CONTACT
EXJADE® (deferasirox) is a Novartis Oncology drug indicated for the treatment of chronic iron overload due to frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.
EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:
- in patients with other anemias,
- in patients aged 2 to 5 years,
- in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
EXJADE Press Releases
09-Dec-2008
04-Dec-2008
EXJADE Additional Materials
-
01-Dec-2008
Long-Term use of EXJADE® (deferasirox) in Patients with Sickle Cell Disease and Transfusional Iron Overload -
24-Nov-2008
Managing Iron Overload in Myelodysplastic Syndromes (MDS) Fact Sheet -
24-Nov-2008
Myelodysplastic Syndromes and Iron Overload Fact Sheet -
19-Nov-2008
Thalassemia and Iron Overload Fact Sheet -
11-Nov-2008
Sickle Cell Disease and Iron Overload Fact Sheet -
9-Jun-2008
EXJADE Fact Sheet -
9-Jun-2008
Iron Overload Fact Sheet
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.